Cancer Monoclonal Antibody Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Description

The report on the global cancer monoclonal antibody market provides qualitative and quantitative analysis for the period from 2021-2030. The monoclonal antibody market was valued at around USD 51.2 billion in 2022 and is expected to reach USD 93.5 billion in 2030, with a CAGR of 6.8% during the forecast period 2023-2030. The study on cancer monoclonal antibody market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

Monoclonal Antibody (mAb) are artificially engineered molecules that mimic the immune system's ability to combat infections by precisely targeting particular pathogens. The process involves extracting B cells from a host exposed to a specific antigen, and fusing these cells with cancer cells to generate hybridomas responsible for producing the desired antibodies. These hybridomas undergo screening, cloning, and large-scale cultivation to produce abundant monoclonal antibodies, subsequently refined through purification for diverse applications. The field continues to evolve, with ongoing innovations enhancing their effectiveness and broadening their scope across medical treatment and scientific investigations. Additionally, an increase in cancer cases is anticipated to drive the monoclonal antibody market. Also, improper work-life balance, unhealthy lifestyle, uncontrolled drug consumption, chemical exposure, and food habits including heavy fat diet and saturated food consumption lead to cancer, thereby it expands the monoclonal antibody market.

Among the above segments, breast cancer is anticipated to dominate the cancer monoclonal antibody market. For instance, according to a report shared by (World Cancer Research Fund International) Breast Cancer was the most common cancer in women worldwide contributing 25.4 % of the total number of new cases diagnosed worldwide. Due to advancements in healthcare technology life expectancy is increased, and obesity, drinking habits, and smoking habits due to improper work-life balance are factors that lead to the risk of breast cancer. Also, the risk of breast cancer rises after 55 years of age, radiological exposure, and hormone replacement therapy are responsible for breast cancer, these are factors that make breast cancer more prevalent and thereby create the demand for cancer treatment, which ultimately drives the cancer monoclonal antibody market.

The cancer monoclonal antibodies are segmented into Asia Pacific, North America, Europe, the Middle East & Africa, and South America. North America is predicted to dominate the cancer monoclonal antibodies market over the forecast period. Across North America, multiple well-developed and various industries, such as agriculture, construction, chemicals, medicines, and food processing, are present. According to estimates from American Health Ranking 2021, there are more than 55.8 million adults in the U.S., who are 65 or older, making up over 16.8% of the total population. In North America advancement in healthcare technologies is responsible for the rising geriatric population, which leads to an increase in diseases such as cancer, which is driving the cancer monoclonal antibody market. In 2023, the United States announced an increase of 12.7% in investment in research and development. In comparison to 2022, is anticipated to further research on the cancer monoclonal antibody market. Food habits in North American countries include: heavy fat, saturated fat-containing products such as hot dogs, salami, lunch meats, jerky, bacon, and other cured meat items that will lead to cancer. This creates a high demand for cancer treatment, which will further drive the cancer monoclonal antibody market. As a result, the above-mentioned factors, rising cancer cases, and investment in R&D will continue to expand the market.

Report Findings

1) Drivers

The market experiences growth propelled by the rising incidence of cancer.
The growth of the market is boosted by the development of diversified treatments.

2) Restraints

High costs associated with the treatment methods hamper the growth of the market.

3) Opportunities

The market presents lucrative growth opportunities due to the rapid increase in healthcare awareness.

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include:

1. Key Opinion Leaders associated with Infinium Global Research

2. Internal and External subject matter experts

3. Professionals and participants from the industry

Our primary research respondents typically include:

1. Executives working with leading companies in the market under review

2. Product/brand/marketing managers

3. CXO level executives

4. Regional/zonal/ country managers

5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications

2. Government/institutional publications

3. Trade and associations journals

4. Databases such as WTO, OECD, World Bank, and among others.

5. Websites and publications by research agencies

Segment Covered

The global cancer monoclonal antibody market is segmented on the basis of antibody type, application, and end user.

The Global Cancer Monoclonal Antibody Market by Antibody Type

Murine
Chimeric
Humanized

The Global Cancer Monoclonal Antibody Market by Application

Blood Cancer
Breast Cancer
Lung Cancer
Others

The Global Cancer Monoclonal Antibody Market by End User

Hospitals and Clinics
Research and Academic Institute/Laboratories

Company Profiles

The companies covered in the report include:

Genentech, Inc.
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Company
Novartis AG
Par Pharmaceutical
CELGENE CORPORATION
Merck & Co., Inc.
Bristol-Myers Squibb Company
Roche Holding AG
AstraZeneca

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the cancer monoclonal antibody market.

2. Complete coverage of all the segments in the cancer monoclonal antibody market to analyze the trends, developments in the global market and forecast of market size up to 2030.

3. Comprehensive analysis of the companies operating in the global cancer monoclonal antibody market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Product Code: IGR01212

Chapter 1. Preface

1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

Chapter 2. Executive Summary

2.1. Cancer Monoclonal Antibody Market Highlights
2.2. Cancer Monoclonal Antibody Market Projection
2.3. Cancer Monoclonal Antibody Market Regional Highlights

Chapter 3. Global Cancer Monoclonal Antibody Market Overview

3.1. Introduction
3.2. Market Dynamics
- 3.2.1. Drivers
- 3.2.2. Restraints
- 3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
- 3.4.1. IGR-Growth Matrix Analysis by Antibody Type
- 3.4.2. IGR-Growth Matrix Analysis by Application
- 3.4.3. IGR-Growth Matrix Analysis by End User
- 3.4.4. IGR-Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Cancer Monoclonal Antibody Market

Chapter 4. Cancer Monoclonal Antibody Market Macro Indicator Analysis

Chapter 5. Company Profiles and Competitive Landscape

5.1. Competitive Landscape in the Global Cancer Monoclonal Antibody Market
5.2. Companies Profiles
- 5.2.1. Genentech, Inc.
- 5.2.2. Dr. Reddy's Laboratories Ltd.
- 5.2.3. Eli Lilly and Company
- 5.2.4. Novartis AG
- 5.2.5. Par Pharmaceutical
- 5.2.6. CELGENE CORPORATION
- 5.2.7. Merck & Co., Inc.
- 5.2.8. Bristol-Myers Squibb Company
- 5.2.9. Roche Holding AG
- 5.2.10. AstraZeneca

Chapter 6. Global Cancer Monoclonal Antibody Market by Antibody Type

6.1. Murine
6.2. Chimeric
6.3. Humanized

Chapter 7. Global Cancer Monoclonal Antibody Market by Application

7.1. Blood Cancer
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Others

Chapter 8. Global Cancer Monoclonal Antibody Market by End User

8.1. Hospitals and Clinics
8.2. Research and Academic Institute/Laboratories

Chapter 9. Global Cancer Monoclonal Antibody Market by Region 2023-2030

9.1. North America
- 9.1.1. North America Cancer Monoclonal Antibody Market by Antibody Type
- 9.1.2. North America Cancer Monoclonal Antibody Market by Application
- 9.1.3. North America Cancer Monoclonal Antibody Market by End User
- 9.1.4. North America Cancer Monoclonal Antibody Market by Country
  - 9.1.4.1. The U.S. Cancer Monoclonal Antibody Market
    - 9.1.4.1.1. The U.S. Cancer Monoclonal Antibody Market by Antibody Type
    - 9.1.4.1.2. The U.S. Cancer Monoclonal Antibody Market by Application
    - 9.1.4.1.3. The U.S. Cancer Monoclonal Antibody Market by End User
  - 9.1.4.2. Canada Cancer Monoclonal Antibody Market
    - 9.1.4.2.1. Canada Cancer Monoclonal Antibody Market by Antibody Type
    - 9.1.4.2.2. Canada Cancer Monoclonal Antibody Market by Application
    - 9.1.4.2.3. Canada Cancer Monoclonal Antibody Market by End User
  - 9.1.4.3. Mexico Cancer Monoclonal Antibody Market
    - 9.1.4.3.1. Mexico Cancer Monoclonal Antibody Market by Antibody Type
    - 9.1.4.3.2. Mexico Cancer Monoclonal Antibody Market by Application
    - 9.1.4.3.3. Mexico Cancer Monoclonal Antibody Market by End User
9.2. Europe
- 9.2.1. Europe Cancer Monoclonal Antibody Market by Antibody Type
- 9.2.2. Europe Cancer Monoclonal Antibody Market by Application
- 9.2.3. Europe Cancer Monoclonal Antibody Market by End User
- 9.2.4. Europe Cancer Monoclonal Antibody Market by Country
  - 9.2.4.1. Germany Cancer Monoclonal Antibody Market
    - 9.2.4.1.1. Germany Cancer Monoclonal Antibody Market by Antibody Type
    - 9.2.4.1.2. Germany Cancer Monoclonal Antibody Market by Application
    - 9.2.4.1.3. Germany Cancer Monoclonal Antibody Market by End User
  - 9.2.4.2. United Kingdom Cancer Monoclonal Antibody Market
    - 9.2.4.2.1. United Kingdom Cancer Monoclonal Antibody Market by Antibody Type
    - 9.2.4.2.2. United Kingdom Cancer Monoclonal Antibody Market by Application
    - 9.2.4.2.3. United Kingdom Cancer Monoclonal Antibody Market by End User
  - 9.2.4.3. France Cancer Monoclonal Antibody Market
    - 9.2.4.3.1. France Cancer Monoclonal Antibody Market by Antibody Type
    - 9.2.4.3.2. France Cancer Monoclonal Antibody Market by Application
    - 9.2.4.3.3. France Cancer Monoclonal Antibody Market by End User
  - 9.2.4.4. Italy Cancer Monoclonal Antibody Market
    - 9.2.4.4.1. Italy Cancer Monoclonal Antibody Market by Antibody Type
    - 9.2.4.4.2. Italy Cancer Monoclonal Antibody Market by Application
    - 9.2.4.4.3. Italy Cancer Monoclonal Antibody Market by End User
  - 9.2.4.5. Rest of Europe Cancer Monoclonal Antibody Market
    - 9.2.4.5.1. Rest of Europe Cancer Monoclonal Antibody Market by Antibody Type
    - 9.2.4.5.2. Rest of Europe Cancer Monoclonal Antibody Market by Application
    - 9.2.4.5.3. Rest of Europe Cancer Monoclonal Antibody Market by End User
9.3. Asia Pacific
- 9.3.1. Asia Pacific Cancer Monoclonal Antibody Market by Antibody Type
- 9.3.2. Asia Pacific Cancer Monoclonal Antibody Market by Application
- 9.3.3. Asia Pacific Cancer Monoclonal Antibody Market by End User
- 9.3.4. Asia Pacific Cancer Monoclonal Antibody Market by Country
  - 9.3.4.1. China Cancer Monoclonal Antibody Market
    - 9.3.4.1.1. China Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.1.2. China Cancer Monoclonal Antibody Market by Application
    - 9.3.4.1.3. China Cancer Monoclonal Antibody Market by End User
  - 9.3.4.2. Japan Cancer Monoclonal Antibody Market
    - 9.3.4.2.1. Japan Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.2.2. Japan Cancer Monoclonal Antibody Market by Application
    - 9.3.4.2.3. Japan Cancer Monoclonal Antibody Market by End User
  - 9.3.4.3. India Cancer Monoclonal Antibody Market
    - 9.3.4.3.1. India Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.3.2. India Cancer Monoclonal Antibody Market by Application
    - 9.3.4.3.3. India Cancer Monoclonal Antibody Market by End User
  - 9.3.4.4. South Korea Cancer Monoclonal Antibody Market
    - 9.3.4.4.1. South Korea Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.4.2. South Korea Cancer Monoclonal Antibody Market by Application
    - 9.3.4.4.3. South Korea Cancer Monoclonal Antibody Market by End User
  - 9.3.4.5. Australia Cancer Monoclonal Antibody Market
    - 9.3.4.5.1. Australia Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.5.2. Australia Cancer Monoclonal Antibody Market by Application
    - 9.3.4.5.3. Australia Cancer Monoclonal Antibody Market by End User
  - 9.3.4.6. Rest of Asia-Pacific Cancer Monoclonal Antibody Market
    - 9.3.4.6.1. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by Antibody Type
    - 9.3.4.6.2. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by Application
    - 9.3.4.6.3. Rest of Asia-Pacific Cancer Monoclonal Antibody Market by End User
9.4. RoW
- 9.4.1. RoW Cancer Monoclonal Antibody Market by Antibody Type
- 9.4.2. RoW Cancer Monoclonal Antibody Market by Application
- 9.4.3. RoW Cancer Monoclonal Antibody Market by End User
- 9.4.4. RoW Cancer Monoclonal Antibody Market by Sub-region
  - 9.4.4.1. Latin America Cancer Monoclonal Antibody Market
    - 9.4.4.1.1. Latin America Cancer Monoclonal Antibody Market by Antibody Type
    - 9.4.4.1.2. Latin America Cancer Monoclonal Antibody Market by Application
    - 9.4.4.1.3. Latin America Cancer Monoclonal Antibody Market by End User
  - 9.4.4.2. Middle East Cancer Monoclonal Antibody Market
    - 9.4.4.2.1. Middle East Cancer Monoclonal Antibody Market by Antibody Type
    - 9.4.4.2.2. Middle East Cancer Monoclonal Antibody Market by Application
    - 9.4.4.2.3. Middle East Cancer Monoclonal Antibody Market by End User
  - 9.4.4.3. Africa Cancer Monoclonal Antibody Market
    - 9.4.4.3.1. Africa Cancer Monoclonal Antibody Market by Antibody Type
    - 9.4.4.3.2. Africa Cancer Monoclonal Antibody Market by Application
    - 9.4.4.3.3. Africa Cancer Monoclonal Antibody Market by End User